It is very important to know under medical treatment which kinds of platelet agonists participate in abnormal platelet-blood vessel interactions.
Introduction
To date, a great deal of attention has been given to platelet-blood vessel interaction (Vanhoutte, at al., 1985 ; Yang, et al., 1994 ; Friedman, et al., 1997) . It is generally accepted that abnormalities in platelet-vascular endothelium interaction often lead to vascular endoth elial dysfunction. Vascular endothelial damage by platelet activation develops frequently in pathological states and/or disorders such as athelosclerosis, vasculitis, hypertension and multiple organ failure.
Also, the kinds of platelet agonists that participate in platelet activa- Tsutomu MICHIBAYASHI tion are particular in cases of vascular thrombosis (Kwaan, et al., 1972 ; Dreifuss, et al., 1973 ; Frishman, et al., 1974) . Platelet activating factor (PAF), a platelet aggregating agent, is a ubiquitous bioactive phospholipid that is generated by different cell types including platelets (Hanahan, et al., 1985) , basophiles (Pinckard, et al., 1979) , and endothelial cells (Zimmerman, et al., 1985 ; Caplan, et al., 1992) . It has been reported that one of the two types of antihyperten sive renomedullary lipids is a highly polar glycerophospholipid designated as antihypertensive polar renomedullary lipid (APRL) and that APRL produces effects similar to those of PAF (Muirhead, et al., 1977 ; Blank, et al., 1979 ; Muirhead, et al., 1981) . In addition, a native or synthetic PAF has been proposed to possess physicochemical and biological properties identical to those previously postulated for APRL (Bessin, et al., 1983 ; Bossant, et al., 1990) . Furthermore, among substances liberated from platelets stimulated by PAF, there are some vasoactive agents that participate in blood vessel contractility (Henson, 1990 ).
The present study was carried out with the aim of elucidating the interaction between platelet aggregating response to PAF and vasoconstrictive response to pressor substances in the presence of platelets with PAF.
Methods

Animals and blood collection
Male Japanese white rabbits weighing 2.5 to 3.0 kg were anesthetized with sodium pentobarbital (30 to 60 mg/kg, i. p.), and heparin (1,000 U/kg, i. v.) was injected into the marginal ear vein (Michibayashi, 1992) . Whole blood was then obtained from each rabbit via femoral artery needle (21 gauge) cannulation and collected into a beaker containing 1/10 vol. of 3.8% sodium citrate. Platelet rich plasma (PRP) was obtained by centrifuging the whole blood at Artery preparation and perfusion conditions An arterial segment was dissected from the proximal portion of each rabbit ear central artery. This segment, about 2.7 cm long, was separately cannulated at the proximal and distal ends with polyethylene tubing and placed in a nearly 5 ml horizontal organ bath (Michibayashi, 1996) . This preparation was then perfused with a modified Krebs solution by means of a roller pump at a constant flow of 3 ml/min. A suitable concentration of NA (0.1 ml), freshly prepared in normal Krebs solution, was injected as a bolus into a rubber tube connected to the central arterial cannula, and then vasoconstrictive response to noradrenaline (NA-R) was observed as the change in perfusionpressure (mmHg). This perfusion pressure change was recorded on a kymographion using a mercury manometer.
For examining platelet-blood vessel interactions, autologous PRP was infused into the perfusion system at a rate of 1 to 3 ml/hr with a Micro Infusion Pump (SP-5, Nipro Co. Ltd., Japan). Under these conditions, the flow rate was increased by about one sixtieth (about 0.05 ml/min) of that during perfusion of the modified normal Krebs solution alone (about 0.05 ml/min) more than that of the preinfusion state. The infusion rate of normal 113 test solution without PRP did not elicit any elevation in basal perfusion pressure.
For examining the action of tetrodotoxin (TTX), a very specific blocker for Na spikes (Hodgkin, et al., 1952 ; Hagiwara, 1983 ; Benoit, et al., 1985) , on NA-R in the presence of PRP infusion was examined under continuous perfusion of TTX .
Studies on platelet aggregating response
A platelet aggregometer (MCMEDICAL, HEMATRACER 212, Japan) was used to exam ine rabbit platelet aggregating response detail. With this apparatus , changes in light transmis sion of the platelet suspension were measured by the turbidimetric method of assessing platelet aggregability. PRP was prepared in the same manner as described above and was stored at decrease in turbidity, and platelet aggregating response was monitored continuously for 20 min .
Also, in the experiments regarding the effects of various drugs on platelet aggregating response, PRP was pretreated with drugs for 30 min before beginning of platelet aggregation .
The drugs used were : 3.8% sodium citrate (Kokusaishiyaku Co ., Japan), platelet activating factor (1-o-alkyl-2-acetyl-sn-glycero-3-physophocholine, Avanti Polar Lipids, Inc., USA), collagen (Worthington Biochemical Co., USA and SIGMA, USA), indomethacin (SIGMA), (-) arterenol bitartrate salt (noradrenaline, SIGMA), tetrodotoxin (Sankyo Co ., Japan), CV-3988 phosphate monosodium (Dibutyryl cyclic AMP, SIGMA). Statistical analysis : All data were analyzed using the F-test and a difference of P < 0.05 was considered to be significant.
Results
In the presence of PRP with PAF, low doses of NA, within a range of 5 to 25 ng, were found to elicit biphasic vascular responses accompanied by unstable elevation of basal perfusion pressure, i. e. an initially augmented response followed by gradually attenuated responses ( Fig.  1 ). In this preparation, platelet aggregation was induced by the addition of PAF into the syringe containig PRP. FAF-treated PRP was infused into the perfusion system immediately after adding PAF into this syringe. Then, during infusion of this PRP, vasocontractile responses to low dose NA were repetitively performed 3 times at 10 min intervals, i. e. 10 min
Next, typical aggregometer tracings of light transmission of rabbit platelets are shown in Fig. 2 . The platelet aggregating response to PAF was increased in a dose-dependent manner ,
and maximum aggregation was noted about 2 min after applying PAF, followed by constant here. In doses of 5 ng/ml (a), 10 ng/ml (b), 50 ng/ml (c), and into each cubette containing PRP. Ordinate indicates light transmission (%).
long-lasting response. In contrast to NA-R (Fig. 1) , light transmission intensity of platelet aggregation induced by PAF very often remained constant . As far as the interaction between platelet aggregation response and NA-R in the presence of PRP with PAF is concerned, the magnitude of platelet aggregation was found not to be directly or strictly linked to vasocon strictive responsiveness.
Subsequently, the effects of CV-3988, an antagonist of PAF (Terashita , et al., 1983) , on platelet aggregating response to PAF and on NA-R during infusion of PRP with PAF were examined.
As a matter of course, CV-3988 apparently suppressed both platelet aggregation a b Fig. 3A . ( Fig. 3A) and NA-R (Fig. 3B) . Following this, the effects of either DBcAMP (Fig. 4) or IM ( (Grottum, et al., 1983 ; Ross, 1993 ; El-Barghouti, et al., 1997) , hypertensive vascular disorder (Hollander, 1976) , vasculitis (Conn, et al., 1988) , collagen disease ( al., 1995) and microangiopathy (Chart, et al., 1991) . Since mechanisms of abnormal platelet endotoxin-positive arteritis and multiple organ failure (Bell, et al., 1991 Chart, et al., 1991 .
Thus, anti-thrombotic therapy should be undertaken in patients under consideration of the platelet agonists that are related to the pathogenesis of vascular thrombosis. The present study, focusing on both PAF and collagen, among the many platelet agonists, was carried out in an attempt to investigate the difference between actions of PAF and collagen in an isolated perfused artery preparation. At first, the effect of PAF on the interaction between platelets and blood vessel contractility was examined during infusion of PRP into the perfusion circuits. Under the infusion of platelets activated by PAF, NA-R showed a biphasic responses, i.e. an initially augmented response followed by gradually attenuated response (Fig.   1 ). Since the former was partially reduced by ketanserin (Michibayashi, 1996) , a selective serotonin 5-HT2 receptor antagonist of 5-hydroxytryptamine (5-HT) liberated from platelets activated by PAF (Henson, 1990) , it is possible that 5-HT is involved in this initially augmented response. While NA-R showed such a biphasic response in the presence of PRP with PAF, the platelet aggregating response to PAF represented a constant long-lasting aggregating magni- Following this, the question as to whether the PAF action through platelets is affected by neurogenic components of the arterial preparation was further evaluated. TTX, a very specific blocker for Na spikes, was used for the purpose of excluding the neurogenic participa tion from the action of PAF on NA-R. Surprisingly, NA-R was reversed to the level of the initial raised response, and the gradually attenuated response disappeared. In addition, we have proposed that TTX does not have any restrictive action on NA-R using the same artery preparation during perfusion of normal test solution alone, although TTX completely blocked vasocontractile response to electrical stimulation of the perivascular sympathetic nerve (Mi chibayashi, 1983) . Based on these findings, it seems reasonable to maintain that the inhibitory action through platelets of PAF on NA-R may be due to vasodepressive agents originating from perivascular autonomic nerves stimulated by unknown substances liberated from platelets activated by PAF. Thus, the data obtained from the present study suggest that the PAF-related aggregating mechanism is rarely influenced by both the adenylate cyclase-cyclic AMP system and cyclo oxygenase metabolic pathway in platelets and to the contrary, the platelet aggregating response to collagen intimately participates in both of them. 
